NEW YORK, N.Y., April 20, 2026 (SEND2PRESS NEWSWIRE) — ViewTech Borescopes, a leading provider of remote visual inspection (RVI) equipment, is returning to exhibit at INTERPHEX, the premier global pharma and biotechnology event. Attendees are invited to visit the ViewTech Borescopes booth 1943 to experience live demonstrations of its industry-leading video borescope technology designed to improve inspection efficiency, safety, and compliance in critical pharmaceutical manufacturing environments.
Category: Biotechnology
ViewTech Borescopes to Demonstrate Clean-In-Place Visual Inspection Solutions at INTERPHEX 2026
NEW YORK, N.Y., April 20, 2026 (SEND2PRESS NEWSWIRE) — ViewTech Borescopes, a leading provider of remote visual inspection (RVI) equipment, is returning to exhibit at INTERPHEX, the premier global pharma and biotechnology event. Attendees are invited to visit the ViewTech Borescopes booth 1943 to experience live demonstrations of its industry-leading video borescope technology designed to improve inspection efficiency, safety, and compliance in critical pharmaceutical manufacturing environments.
BioAustinCTX Announces Leadership Transition
AUSTIN, Texas, March 18, 2026 (SEND2PRESS NEWSWIRE) — BioAustinCTX today announced that Scott Collins, PhD, has transitioned from his role as President at the end of February after more than a decade of leadership supporting the growth of the Central Texas life sciences ecosystem.
Iota Biosciences Founder to Keynote 2026 Bioelectronic Medicine Forum in NYC
NEW YORK, N.Y., March 5, 2026 (SEND2PRESS NEWSWIRE) — Neurotech Reports, the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that the Ninth Annual Bioelectronic Medicine Forum will take place on April 14, 2026. The one-day event will be held at the New York Academy of Medicine in Manhattan.
HLA Protein Technologies Debuts sHLA-G Monomer and Tetramer Portfolio for High-Fidelity Checkpoint Biology, Target Validation, and Assay Development
OKLAHOMA CITY, Okla., Nov. 19, 2025 (SEND2PRESS NEWSWIRE) — HLA Protein Technologies, Inc. (formerly Pure Protein, LLC) today announced the commercial launch of its new soluble HLA-G (sHLA-G) product portfolio, marking an expansion of its next-generation HLA research tools. HLA-G is a non-classical MHC Class I molecule recognized as a key immune checkpoint regulator.
HLA Protein Technologies Announces Next-Gen HLA Product Lines and Strategic Investment
OKLAHOMA CITY, Okla., Sept. 30, 2025 (SEND2PRESS NEWSWIRE) — HLA Protein Technologies, Inc. (formerly Pure Protein, LLC) reports that its new manufacturing expansion is positioned to support the Company’s growth. A new product line launch, a strategic investment led by a private investor group; and a corporate rebrand to HLA Protein Technologies, reflects the company’s expanded focus on advanced immunology and oncology research tools.
Two Prominent Professors to Keynote 25th Annual Neurotech Leaders Forum
SAN FRANCISCO, Calif., Aug. 11, 2025 (SEND2PRESS NEWSWIRE) — Neurotech Reports, the publisher of the Neurotech Business Report newsletter, announced that two prominent figures in the field of neurotechnology will keynote the 2025 Neurotech Leaders Forum, which takes place November 5-6 in San Francisco. Edward Chang, chair of the department of neurological surgery at UC San Francisco, will discuss future applications of implanted brain sensing and stimulation devices.
Zeteo Biomedical Secures Global Patents for Nasal and Ophthalmic Drug Delivery Device Innovations
CEDAR PARK, Texas, June 11, 2025 (SEND2PRESS NEWSWIRE) — Zeteo Biomedical, a privately held biomedical device company, today announced the issuance of new patents in the United States and European Union for its advanced drug delivery technologies. The patents, titled “Cartridge Devices for Administration of a Medicament” (U.S. Patent No. 12329949) and “Hand-Operated Devices for Administration of a Medicament” (EU Patent No. 3946526), further strengthen Zeteo’s ZTech™ delivery platform portfolio for the administration of drugs and biologics via nasal, ophthalmic, and sublingual routes.
Imaging with Precision: Amerigo Scientific Announces Different-Sized Bioconjugated Fluorescent Nanodiamonds
NEW YORK, N.Y., May 9, 2025 (SEND2PRESS NEWSWIRE) — Amerigo Scientific unveils its line of different-sized bioconjugated fluorescent nanodiamonds (FNDs), designed to redefine precision in cellular and in vivo imaging. These bioconjugated FNDs are provided to address critical challenges in high-resolution diagnostics, targeted drug delivery, and real-time biological tracking, positioning itself as a game-changer for researchers and scientists alike.
Redox Therapeutics Signs Exclusive License Agreement with The Curators of the University of Missouri to Create Filtration Technology to Address Healthcare and Environmental Needs
PHILADELPHIA, Pa., April 29, 2025 (SEND2PRESS NEWSWIRE) — Redox Therapeutics announces the signing of an exclusive license agreement with The Curators of the University of Missouri acting by and through the Missouri University of Science and Technology (Missouri S&T) for a patented polymer nanoparticles technology designed for endotoxin removal from fluids such as water, protein solutions and plasma.